Assets Mechanisms Companies Calendar Charts Watchlist Ask AI Methodology

Cardiovascular & Metabolic506
Dermatology157
Gastroenterology & Hepatology173
Hematology29
Immunology149
Infectious Disease118
Nephrology108
Neurology466
Oncology1,082
Ophthalmology40
Psychiatry141
Rare & Genetic Diseases49
Respiratory140

⌕

Evidence-graded drug-asset intelligence

Assets Mechanisms Companies Readout Calendar Compare Charts Watchlist & Alerts Ask AI

Therapeutic areas

Cardiovascular & Metabolic506
Dermatology157
Gastroenterology & Hepatology173
Hematology29
Immunology149
Infectious Disease118
Nephrology108
Neurology466
Oncology1,082
Ophthalmology40
Psychiatry141
Rare & Genetic Diseases49
Respiratory140

ReferenceMethodology & Rubric Us vs. AI Tools UK IBD Access Guide

Educational data tool. Evidence graded; securities never are.

Home
Mechanisms
IL-13 x IL-31

Mechanism

IL-13 x IL-31

Assets acting on this target.

Class: Bispecific engineered attobody

← all mechanisms

BrowseAll assets All mechanisms All companies Readout calendar Compare share prices What's new

ReferenceMethodology & sources Us vs. the AI tools UK IBD Access Guide Ask the AI Report a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

Company

Attovia Therapeutics (1)

1 of 1 assets

Multispecific antibodyPhase 1